GlassScriptPhysician profile
David Sine
NPI 1124187018
$251.33
in general payments reported to CMS, 2019-2025
10 companies · none reported in 2025
Payments by year
General and research payments by program year, as reported to CMS.
General payments by year: 2019: $15.16 · 2020: $38.44 · 2021: $63.26 · 2022: $134.
Who reported paying
General payments only, as reported to CMS. Research payments are listed separately below. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $58.64 | 2021-2022 | |
| Supernus Pharmaceuticals, INC. | $44.80 | 2022 | |
| Advanced Respiratory, INC | $35.59 | 2021 | |
| Novartis Pharmaceuticals Corporation | $32.97 | 2022 | |
| Cranial Technologies, INC | $21.09 | 2020 | |
| Sobi, INC | $17.35 | 2020 | |
| Merck Sharp & Dohme LLC | $15.16 | 2019 | |
| Baxter Healthcare | $13.88 | 2022 | |
| Sanofi Pasteur INC. | $11.85 | 2021 |
1 company reported research payments only; those appear in the research section below.
Research and ownership
$2,313.58 in research payments reported 2019-2025. Research payments are often institution-directed and tied to clinical trials: they are reported under a clinician's name but frequently go to a hospital or research organization, and usually reflect participation in medical research.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Sine listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.